The company's positioning has been changed from a single product to the layout of the entire industrial chain and is committed to exploring a practical model in China's health undertakings. The company has always been in a leading position in molecular biology technologies, especially the research, development, and application of gene diagnosis technology and reagent products, independently developed the fluorescence quantitative PCR gene diagnosis technology, and has more than hundred medical device registration certificates, more than 50 CE certificates, and six CMDCAS certificates, besides 54 products were identified as high-tech products in Guangdong province, which provides a powerful guarantee for our products entering the domestic and international market. Meanwhile, the company sought for transformation, explored actively, built a value system featuring openness, sharing, cooperation, and win-win results, implemented the open mode of the all-around platform, shared the value of growth, and committed to the health care integration of upstream and downstream suppliers in the field of a strategic goal. At present, over 300 health care enterprises were invested by the company in the incubator model, which completed our layout of the whole industry chain, and we hope to make our contribution to the health industry in China.
In recent years, the company has undertaken many national projects and won awards, such as the national "863" project, "973" project, "ninth five-year plan", "tenth five-year plan", and "eleventh five-year plan".